12.         Stock-based Compensation

Shares available for grant

On May 16, 2025, the Company held its 2025 Annual Meeting of Stockholders (the "Annual Meeting") and ratified an amendment to the Company's Amended and Restated 2014 Equity Incentive Plan (the "2014 Plan") to increase the total number of shares of common stock authorized for issuance by 153 shares. As of March 31, 2026, the total number of shares authorized for grant under the 2014 Plan was 468, of which approximately 1 were available for future grants.

Restricted Stock Units

The Company issues time-based restricted stock units (“RSUs”) to employees and non-employees. Each RSU represents the right to receive one share of the Company’s common stock upon vesting and subsequent settlement. The fair values of RSUs are determined based on the closing price of the Company’s common stock on the date of grant.

RSU activity for the three months ended March 31, 2026 is summarized below:

The total grant-date fair value of RSUs that vested during the three months ended March 31, 2026 was $32. As of March 31, 2026, $173 of total unrecognized compensation expense related to unvested RSUs was expected to be recognized over a weighted average period of 1.12 years.

Stock Options

The following table summarizes information about the Company's stock options outstanding as of March 31, 2026:

No stock options were granted or exercised during the three months ended March 31, 2026 and 2025.

As no stock options were granted during the three months ended March 31, 2026 and 2025, there was no related weighted-average grant date fair value. The total grant date fair value of stock options vested during the three months ended March 31, 2026 and 2025 was $0.

As of March 31, 2026, total unrecognized compensation cost related to unvested stock options was $0.

Compensation Expense

Stock-based compensation expense is included in the condensed consolidated statements of operations and comprehensive loss in general and administrative, research and development, or sales and marketing expenses, depending on the nature of the services provided. Stock-based compensation expense related to RSUs was recorded as follows:

401(k) Plan Share Match

During the three months ended March 31, 2026, the Company paid $265 in cash to eligible employees’ deferral accounts for the Ekso Bionics 401(k) plan (the "401(k) Plan") matching contribution representing 50% of each eligible employee’s elected deferral (up to the statutory limit) for the year ended December 31, 2025.

During the three months ended March 31, 2025, the Company issued 37 shares of common stock with a fair value of $236 to eligible employees’ deferral accounts for the 401(k) Plan matching contribution representing 50% of each eligible employee’s elected deferral (up to the statutory limit) for the year ended December 31, 2024. The expense, net for the 401(k) Plan share matching was $(25) for the three months ended March 31, 2025.